We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The University of Oxford is gearing up to launch a trial of the anti-inflammatory drug adalimumab as a treatment for COVID-19 patients in community care homes. Read More
Regeneron Pharmaceuticals yesterday unveiled early data on its COVID-19 antibody cocktail in which the drug appeared to provide a benefit for nonhospitalized COVID-19 patients. Read More
GlaxoSmithKline (GSK) has launched a phase 2 trial in the UK of its investigational rheumatoid arthritis treatment otilimab for hospitalized COVID-19 patients. Read More
Interim results from a phase 1 trial showed that INO-4800 was safe and well-tolerated and induced immune responses in a majority of participants. Read More
The FDA has placed a partial clinical hold on Inovio Pharmaceuticals’ planned phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, calling for more information. Read More
Early trial data from Johnson & Johnson’s COVID-19 vaccine candidate AD26.COV2.S has shown that a single dose was enough to generate a strong antibody response. Read More
The UK is launching the first COVID-19 challenge trials, in which healthy volunteers will be exposed to the virus to assess the safety and effectiveness of vaccine candidates, the government says. Read More
Novavax yesterday launched a phase 3 clinical trial of its COVID-19 vaccine in the UK, becoming the latest drugmaker to bring a vaccine candidate to late-stage testing. Read More
The company said it will conduct a detailed analysis of the data and will plan to file for approval of Avigan in Japan for this indication as soon as next month. Read More